Amanta Healthcare Limited, founded in 1994 and headquartered in Ahmedabad, Gujarat, is a pharmaceutical company specializing in sterile liquid products. It develops and markets Large Volume Parenterals (LVPs), Small Volume Parenterals (SVPs), ophthalmic solutions, irrigation solutions, respiratory care products, and medical devices.
The company operates a WHO-GMP certified manufacturing facility at Hariyala, Kheda, Gujarat, equipped with ABFS (Aseptic Blow Fill Seal) and ISBM (Injection Stretch Blow Moulding) technologies. The facility also includes a quality laboratory for testing and a dedicated formulation unit to support new product development.
Amanta Healthcare IPO: A New Era in Irrigation Solutions
Among its therapeutic segments, the company manufactures and markets irrigation solutions alongside fluid therapy formulations and ophthalmic solutions. The company exported branded products to international markets, ensuring regulatory compliance and product registration in multiple countries. These products are exported as branded products to Latin America and other global markets, contributing significantly to international sales.
Introduction to Irrigation Solutions
Irrigation solutions form a vital component of Amanta Healthcare Limited’s diverse product portfolio, reflecting the company’s commitment to delivering high-quality sterile liquid products to the global pharmaceutical market. As a leading pharmaceutical company, Amanta Healthcare has built a reputation for excellence in manufacturing and marketing a comprehensive range of products, including fluid therapy formulations, ophthalmic solutions, and respiratory care offerings.
At the heart of Amanta Healthcare’s operations is its advanced manufacturing facility in Hariyala, Kheda, Gujarat. This state-of-the-art plant is equipped with cutting-edge technologies such as Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM), enabling the efficient production of both large volume parenterals (LVPs) and small volume parenterals (SVPs). These technologies ensure that the company’s irrigation solutions meet the highest standards of sterility and safety, which is essential for pharmaceutical applications.
Amanta Healthcare’s irrigation solutions are engineered to provide reliable and effective fluid delivery, catering to a wide spectrum of medical needs. The company offers a variety of closure systems and container fill volumes, allowing healthcare providers to select the most suitable packaging for their requirements. This flexibility, combined with a robust distribution network and an experienced management team, positions Amanta Healthcare as a preferred partner for hospitals, clinics, and healthcare professionals worldwide.
In response to growing market demand, Amanta Healthcare has made significant capital expenditure investments to expand its manufacturing capacity. The company has recently set up new SVP manufacturing lines at its Hariyala facility and invested in the latest equipment, plant, and machinery, including advanced blow moulding ISBM technologies. These enhancements are designed to support the company’s strategic growth objectives, enabling it to broaden its product portfolio and increase its market share in the competitive pharmaceutical industry.
The recently announced Amanta Healthcare Limited IPO is a key milestone in the company’s growth journey. The funds raised will be directed towards capital expenditure requirements, including the purchase of equipment, plant, and machinery, as well as civil construction work to further upgrade the manufacturing facility. This infusion of capital is expected to accelerate the company’s expansion plans, strengthen its manufacturing and marketing capabilities, and reinforce its leadership in sterile liquid manufacturing.
With a steadfast focus on quality, innovation, and customer satisfaction, Amanta Healthcare Limited is well-positioned to capture new opportunities in the global pharmaceutical market. The company’s skilled workforce, advanced ISBM technologies, and strong distribution network make it an attractive choice for retail investors, qualified institutional buyers, and non-institutional investors seeking exposure to the healthcare sector. As Amanta Healthcare continues to invest in new manufacturing lines and expand its product offerings, it is set to play a pivotal role in shaping the future of pharmaceutical irrigation solutions.
Amanta Healthcare Limited: Core Business & Verticals
Amanta operates across the following therapeutic and business segments:
- Fluid Therapy: A comprehensive range of fluids diluents ophthalmic solutions, including IV fluids, diluents, and formulations used in hospitals, first aid products, and critical care. The company has expertise in manufacturing IV fluids diluents ophthalmic using advanced technologies.
- Pharmaceutical Formulations: Ophthalmic solutions (eye lubricants), respiratory care, anti-infectives, diuretics, and other pharmaceutical products.
- Medical Devices: Plastic containers and closure systems (nipple head, leur-lock, twist-off, screw type), forming part of the medical device segment.
- Branded Products & Exports: The company exports to 47+ countries, including Latin America, contributing ~33% of revenues from national sales and international sales.
Amanta Healthcare Limited IPO
IPO Details
| Particulars | Details |
|---|---|
| Issue Size | Up to 1,00,00,000 equity shares (Face Value ₹10 each) |
| Type | 100% book-built issue |
| Price Band | To be announced 2 working days before opening |
| Issue Dates | Opens: September 1, 2025 → Closes: September 3, 2025 |
| Anchor Investor Date | August 29, 2025 |
| Tentative Listing Date | September 2025 |
| Book Running Lead Manager (BRLM) | Beeline Capital Advisors Pvt. Ltd. |
| Registrar | Shanti Capital |
| Objects of the Issue | 1. ₹7,000 lakh – Setting up new SteriPort LVP manufacturing line at Hariyala Kheda Gujarat 2. ₹3,013.11 lakh – Setting up new SVP manufacturing lines at Hariyala 3. Balance – General corporate purposes |
The net issue proceeds will go towards funding capital expenditure requirements, including civil construction work, purchase of equipment plant and machinery, and towards purchase of equipment for new lines.
Particulars
| Particulars | Details |
|---|---|
| Price Band | The price band will be announced prior to opening, with details published in Financial Express (English & Gujarati) and Jansatta editions as required by SEBI. |
| Allotment Status | Retail investors can check the allotment status on the website of the registrar, Shanti Capital, after finalization. |
| ISBM Technologies | Amanta is one of the few Indian players using stretch blow moulding ISBM technologies combined with seal ABFS and injection systems. These technologies ensure contamination-free sterile liquid manufacturing, a key differentiator in the healthcare limited IPO space. |
The IPO is part of India’s growing healthcare IPO trend, with demand for sterile liquid manufacturing and pharmaceutical formulations rising across six therapeutic segments. The company manufactures and markets products under its SteriPort manufacturing line of SVP and LVP, supported by three SVP manufacturing lines already in operation.
Manufacturing Facility
The facility at Hariyala is equipped with:
- Four LVP lines – including blow moulding ISBM technologies and aseptic blow fill seal (ABFS).
- Three SVP lines – including injection stretch blow moulding and ABFS and injection stretch.
- A manufacturing line for SVP under construction.
- A manufacturing line of SteriPort being set up through IPO funds.
Milcent Appliances Private Limited is one of the promoters and key stakeholders involved in the ownership and management of the facility.
Fluid Therapy
Amanta is a major player in fluid therapy formulations, producing IV fluids, diluents, and ophthalmic solutions. These products are packaged in plastic containers of varying container fill volumes, with strong demand from hospitals, clinics, and retail markets.
Pharmaceutical Formulations
The company manufactures pharmaceutical formulations including ophthalmic solutions, eye lubricants, diuretics, anti-infectives, and respiratory care. Its pharmaceutical products are sold in both domestic distribution networks and international sales markets.
Financial Overview (₹ in Cr)
| Particulars | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue from Operations | 257.84 | 294.62 | 332.55 |
| EBITDA | 44.96 | 52.39 | 61.41 |
| EBITDA Margin (%) | 17.4% | 17.8% | 18.5% |
| Profit After Tax (PAT) | 15.83 | 20.06 | 25.28 |
| PAT Margin (%) | 6.1% | 6.8% | 7.6% |
| Net Worth | 88.52 | 106.92 | 123.71 |
| Total Debt | 156.70 | 198.20 | 252.40 |
| Debt-to-Equity Ratio | 1.77x | 1.85x | 2.04x |
The company operates at high utilization levels, making its capital expenditure requirements towards setting up new manufacturing lines critical for future growth.
Revenue, EBITDA & PAT
Amanta Healthcare has shown consistent revenue growth from ₹258 Cr in FY23 to ₹333 Cr in FY25. Both EBITDA and PAT have risen steadily, indicating strong operational performance.
Margins Trend
EBITDA margin improved from 17.4% in FY23 to 18.5% in FY25, reflecting efficiency gains. PAT margin also expanded to 7.6%, showing better bottom-line strength.
Debt vs Net Worth
Total debt has increased significantly to ₹252 Cr in FY25, outpacing net worth of ₹124 Cr. This highlights the company’s reliance on borrowings to fund expansion.
Debt-to-Equity Ratio
The leverage ratio has climbed from 1.77x in FY23 to 2.04x in FY25. While this supports capacity expansion, it also raises financial risk for investors.
Strengths
- Established player in sterile liquid pharmaceuticals with WHO-GMP certifications.
- Diversified therapeutic segments – IV fluids, ophthalmics, respiratory care, medical device segment.
- Strong distribution network across 47+ countries with both national sales and exports.
- Advanced ABFS & ISBM technologies ensuring quality sterile production.
- Skilled workforce and experienced management team.
Peer comparison
| Company | Revenue (FY25) | EBITDA Margin (%) | PAT Margin (%) | Debt/Equity | Key Segments |
|---|---|---|---|---|---|
| Amanta Healthcare Ltd. | 332.55 | 18.5% | 7.6% | 2.04x | IV Fluids, SVPs, Ophthalmics, Respiratory Care, Medical Devices |
| Denis Chem Lab Ltd. | 200 | 15–16% | 5–6% | 1.2x | IV Fluids, Ophthalmics, Irrigation Solutions |
| Otsuka India Ltd. | 460 | 13–14% | 4–5% | 0.6x | LVPs, SVPs, Electrolytes, Nutrition Solutions |
| Fresenius Kabi India (Unlisted, Parent Listed Abroad) | 1,200 | 12–14% | 3–4% | 0.5x | Parenterals, Clinical Nutrition, Oncology Injectables |
| Aculife Healthcare (Part of Nirma Group, Unlisted) | 1,800 | 15% | 5% | 0.7x | IV Fluids, Infusion Therapy, Ophthalmics, Critical Care |
Risks
- High leverage (Debt/Equity 2.04x) raises financing risk.
- Heavy dependence on IV fluids formulations and fluid therapy segment.
- Execution risk in setting up new manufacturing line of SteriPort and SVP at Hariyala Kheda Gujarat.
- Competition from Aculife, Fresenius Kabi, Otsuka, Denis Chem Lab.
- Regulatory and compliance challenges for international sales.
Conclusion
Amanta Healthcare Limited is a well-established pharmaceutical company with a strong presence in sterile liquid manufacturing, fluid therapy, pharmaceutical formulations, and medical devices. The IPO aims at funding capital expenditure requirements for setting up new manufacturing lines, particularly a SteriPort LVP line and SVP manufacturing lines at Hariyala, Gujarat.
While civil construction work, purchase of equipment plant and machinery, and debt leverage pose risks, the company’s experienced management team, skilled workforce, advanced ISBM technologies, and strong branded product exports provide a compelling growth.
Disclaimer: The information provided in our blogs is for informational purposes only and should not be construed as financial, investment, or trading advice. Trading and investing in the securities market carries risk. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results. Copyrighted and original content for your trading and investing needs.
© 2025 — Tradejini. All Rights Reserved.
